Novartis Pharmaceuticals Corporation, USA
Raoudha Soufi -Mahjoubi MD is Senior Medical Director of US Oncology at Novartis Pharmaceutical Corporation. She obtained her medical degree from Faculté de Médecine, Tunis and specialized in Medical Oncology at Université René Descartes, Paris. She has academic experience in medical oncology, and has 18 years of experience in the pharmaceutical industry with a strong expertise in clinical research and drug development in oncology.
Activation of the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway in cancer is associated with tumor growth, progression, and the development of resistance to anticancer therapy. PI3K is therefore a promising target for drug development. Various PI3K inhibitors are currently under evaluation in clinical trials, including the pan-PI3K inhibitor buparlisib (BKM120) and the PI3Kα-specifi c inhibitor alpelisib (BYL719). Early clinical studies with these compounds indicated the safety profi les were manageable, with mostly on-target adverse events, such as hyperglycemia. Early signs of clinical activity were also observed. However, consistent with preclinical models suggesting PI3K inhibition can overcome resistance to other anticancer drugs, the greatest opportunities for these compounds appear to be in combination, particularly with endocrine and other targeted therapies. Buparlisib is currently being evaluated in various combinations in Phase III studies in breast cancer, including BELLE-2 and BELLE-3, and Phase II studies in other indications. Alpelisib isbeing evaluated in combination in Phase II studies in breast cancer and head and neck cancer, among other indications. As these compounds advance through clinical development,several questions remain. In particular, which PI3K inhibitor is likely to be most eff ective in which tumor type, and what biomarker will predict the patient population most likely to benefi t from PI3K inhibitor therapy? Novartis is employing a fl exible approach to biomarker-driven study design to address these questions and maximise the benefi ts of clinical studies with buparlisib and alpelisib. An overview of the Novartis PI3Kinhibitor program utilising these approachesin diff erent cancers will be described.